Michael Gurell, MD
Pulmonary Disease · Rochester, NYNPI 1194834366
Payments from drug & device makers
Across 195 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$682
- Boehringer Ingelheim$259
- Mylan Specialty L.p.$252
- Amgen$231
- Insmed, Inc.$210
- plus $943 from 13 others
What the payments were for
- Food & beverage$3,95299%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 76 | $1,398 |
| AstraZeneca | 40 | $682 |
| Boehringer Ingelheim | 11 | $259 |
| Mylan Specialty L.p. | 12 | $252 |
| Amgen | 9 | $231 |
| Insmed, Inc. | 12 | $210 |
| Regeneron Healthcare Solutions, Inc. | 7 | $182 |
| Electromed, Inc. | 4 | $158 |
| Sanofi | 4 | $144 |
| Grifols USA, LLC | 6 | $115 |
| Bayer | 4 | $78 |
| Verona Pharma, Inc. | 2 | $68 |
| Pulmonx Corporation | 1 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Pfizer | 2 | $31 |
| Olympus America Inc. | 1 | $28 |
| Circassia Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$105
How this compares
$3,974 in reported general payments places this provider in the 65th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 14 | $243,514 |
| NucalaMepolizumab | 45 | $159,658 |
| Dupixent PenDupilumab | 39 | $134,830 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $90,427 |
| Spiriva RespimatTiotropium Bromide | 41 | $27,185 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $15,235 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $15,101 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $12,603 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 55 | $11,492 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $8,381 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $8,189 |
| DalirespRoflumilast | 18 | $7,520 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $7,417 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 39 | $7,071 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $3,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $259 | $291,68380 claims |
| GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,398 | $288,610247 claims |
| AstraZenecaDaliresp, Symbicort | $682 | $14,93752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Rochester
- R WhiteRochester$3.1M
- Daniel LachantRochester$1.6M
- Robert KottmannRochester$913K
- Steve GeorasRochester$269K
- Michael LarjRochester$230K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.